Because APOC3 and ANGPTL3 are both under consideration as therapeutic targets for CVD prevention26, we next contrasted the effects of silencing hepatic APOC3 versus ANGPTL3 on diabetic dyslipidemia, arterial lipid accumulation, and initiation of lesions of atherosclerosis. The gene discussed is ANGPTL3; the disease is atherosclerosis.